The Food and Drug Administration last week authorized the emergency use of a third diagnostic test that detects and differentiates flu and COVID-19 viruses from one another. 

The test from the Centers for Disease Control and Prevention, along with previously authorized tests from BioFire Diagnostics LLC and QIAGEN GmbH, require only a single sample from patients who exhibit respiratory disease symptoms. FDA said these tests will use fewer supplies and provide faster and comprehensive results.

Related News Articles

Headline
The Administration for Strategic Preparedness and Response June 25 announced a flu pandemic preparedness and response strategy in response to the threat of…
Headline
The Food and Drug Administration last week granted enforcement discretion for the use of conjunctival swabs by laboratories as part of human testing for H5N1…
Headline
The Centers for Disease Control and Prevention May 21 announced recommendations that flu surveillance systems continue operating at enhanced levels during the…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…
Headline
Flu-associated medical visits and hospitalizations per 100,000 population in 2022-23 were higher among children under age 5 than for older children, but were…